Patent · US Active

MET antibody drug conjugates

US11167039B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Yiqing Feng · Chesterfield, US
Philip Arthur Hipskind · New Palestine, US
Renhua Li · Wilmington, US
Ling Liu · Carmel, US
Takako WILSON · Indianapolis, US
Aaron D. Wrobleski · Indianapolis, US

Key dates

Filing date	Nov 17, 2017
Grant date	Nov 9, 2021
Priority date	—
Expiry date	Feb 6, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.